Virginia Commonwealth University

VCU Massey Cancer Center

Novel combination therapy developed at Massey shows strong response in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. Approximately 61 percent of these patients experienced some degree of tumor growth delay, with multiple partial responses and one complete response. A phase 2 study testing the same combination of the drugs sorafenib and pemetrexed in patients with recurrent or metastatic triple negative breast cancer is now open at Massey. 

Continue reading →

VCU Massey researchers encouraged by Vice President Biden’s $70 million Genomics Data Commons project

Researchers from Virginia Commonwealth University (VCU) Massey Cancer Center were in attendance at the American Society for Clinical Oncology’s annual meeting in Chicago when Vice President Joe Biden announced that more than $70 million would be invested in the development of the Genomics Data Commons (GDC), an information center housed at the University of Chicago and funded by the National Cancer Institute (NCI) to help facilitate the sharing of genomic and clinical data among cancer researchers in order to advance personalized medicine.

Continue reading →

Two clinical trials test novel combination therapies for brain and central nervous system cancers

Paul Dent for blog

Researchers at VCU Massey Cancer Center are conducting two clinical trials testing novel combination therapies for the treatment of brain and central nervous system cancers. The phase 1 and phase 2 clinical trials are both based on translational research performed at Massey by Paul Dent, Ph.D., Universal Corporation Chair in Cancer Cell Signaling and member of the Cancer Cell Signaling research program at VCU Massey as well as professor of biochemistry and molecular biology at VCU School of Medicine. 

Continue reading →

Clinical trial tests promising immunotherapies for advanced lung cancer

Sherman Baker Jr., M.D., medical oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center, is spearheading a phase 3 clinical trial testing two immunotherapy drugs, MEDI4736 and tremelimumab, for the treatment of patients with advanced lung cancer. The goal of the study is to determine whether MEDI4736 combined with tremelimumab or MEDI4736 by itself is more effective than traditional chemotherapy treatment to treat advanced lung cancer.

Continue reading →

Massey researcher awarded $3 million to study the effect of blood cell stimulation on the development of adolescent leukemia and bone marrow disorders

Massey program leader, researcher and physician Seth Corey M.D., M.P.H., was awarded more than $3 million in grant funding from the National Heart, Lung and Blood Institute (NHLBI) for a four-and-a-half-year study on the evolution of a blood cell deficiency to pre-leukemia. The research aims to determine whether a common treatment for the condition acts as a contributor to the development of leukemia or other life-threatening bone marrow disorders.

Continue reading →